Showing 5391-5400 of 5909 results for "".
- Canon USA to Showcase Eyecare Solutions At AAOhttps://modernod.com/news/canon-usa-to-showcase-eyecare-solutions-at-aao/2476971/Canon U.S.A. will be showcasing the recently FDA 510(k) cleared Xephilio OCT-A1 Optical Coherence Tomography device, together with the required RX Capture software, computer and LCD monitor,collectively, the “Xephilio OCT-A1 System, at the American Academy o
- QuickSee Handheld Autorefractor Shows Strong Agreement With Subjective Refraction Measurementshttps://modernod.com/news/quicksee-handheld-autorefractor-shows-strong-agreement-with-subjective-refraction-measurements/2476968/PlenOptika, maker of the QuickSee handheld autorefractor, announced the publication of research showing their device produces measurements in strong agreement with subjective refraction and traditional autorefraction technology. The paper “<
- Ex-Shire CEO Flemming Ornskov Emerges as Galderma CEO after $10B Nestlé Spinouthttps://modernod.com/news/ex-shire-ceo-flemming-ornskov-emerges-as-galderma-ceo-after-10b-nestle-spinout/2476966/As Takeda folds in Shire, two of the Irish rare disease specialist’s former top leaders have found themselves a new home at Nestlé skin health spinoff Galderma, according to a report in FiercePharma. Flemming Ornskov, Shire’s most recent CEO before the Takeda buyout, has
- Alcon to Highlight AcrySof IQ PanOptix Trifocal IOL Launch and New IOL Data at AAOhttps://modernod.com/news/alcon-to-highlight-acrysof-iq-panoptix-trifocal-iol-launch-and-groundbreaking-iol-data-at-aao/2476961/Alcon announced its plans to lead a wide range of informational and peer-to-peer educational programs at the American Academy of Ophthalmology (AAO) annual meeting on October 12-15 in San Francisco. The newly launched AcrySof IQ PanOptix Trifocal IOL, along with findings from the AAO IRIS (Intell
- Eyeris Announces Industry-First, Environmentally-Conscious Packaginghttps://modernod.com/news/eyeris-announces-industry-first-environmentally-conscious-packaging/2476959/Nashville-based start-up Eyeris recently announced its daily disposable contact lens that will be launching in January of 2020. Along with the lens, Eyeris created industry-first trial lens packa
- Allegro to Present Clinical Research on the Novel Integrin-Regulating Portfolio at AAOhttps://modernod.com/news/allegro-to-present-clinical-research-on-the-novel-integrin-regulating-portfolio-at-aao/2476956/Allegro Ophthalmics announced that the results of its phase 2 clinical study of risuteganib (Luminate) for the treatment of intermediate nonexudative age-related macular degeneration (AMD) will be presented during AAO
- Novartis Receives FDA Approval for Beovu for Wet AMDhttps://modernod.com/news/novartis-receives-fda-approval-for-beovu-for-wet-amd/2476953/Novartis announced that the FDA approved Beovu (brolucizumab-dbll) injection, also known as RTH258, for the treatment of wet age-related macular degeneration (AMD). Beovu is the first FDA approved anti-VEGF to offer both greater fluid resolution versus aflibercept and the ability to maintain elig
- Johnson & Johnson Vision Launches Worldwide #ConnectedBySight Campaign in Honor of World Sight Dayhttps://modernod.com/news/johnson-johnson-vision-launches-worldwide-connectedbysight-campaign-in-honor-of-world-sight-day/2476949/In honor of World Sight Day on October 10, 2019, Johnson & Johnson Vision has launched a worldwide campaign to share the untold stories of eye care professionals, patients, and organizations who are inspiring the elevation of eye health as a global priority and demonstrating how the world is
- Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Clinical Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-announces-dosing-of-first-patient-in-randomized-phase-2b-skyggn-clinical-trial-of-ocs-01-for-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2476947/Oculis announced the dosing of the first patient in a phase 2b clinical trial evaluating the efficacy and safety of OCS-01 for the treatment of inflammation and pain following cataract surgery. OCS-01 is a unique topical formulation of dexamethasone based on the company’s proprietary
- TECLens and SERVImed Industrial Spa Announce Partnership to Pursue FDA Approval for Transepithelial Corneal Cross-Linkinghttps://modernod.com/news/teclens-and-servimed-industrial-spa-announce-partnership-to-pursue-fda-approval-for-trans-epithelial-corneal-cross-linking/2476941/Medical device manufacturer TECLens announced a partnership with Italian medical device maker SERVimed Industrial Spa aimed at the development and FDA approval of a new combination product to treat keratoconus. The ne